Experimental Hematology
Volume 38, Issue 10 , Pages 885-895 , October 2010

Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor−related apoptosis-inducing ligand-mediated apoptosis

  • Koshi Akahane

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Takeshi Inukai

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • Corresponding Author InformationOffprint requests to: Takeshi Inukai, M.D., Department of Pediatrics, School of Medicine, University of Yamanashi, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
    • ,
  • Xiaochun Zhang

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Kinuko Hirose

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Itaru Kuroda

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Kumiko Goi

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Hiroko Honna

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Keiko Kagami

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Shinpei Nakazawa

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Kazushi Endo

      Affiliations

    • Department of Epigenetic Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Takeo Kubota

      Affiliations

    • Department of Epigenetic Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan
    • ,
  • Hideo Yagita

      Affiliations

    • Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
    • ,
  • Toshiko Koyama-Okazaki

      Affiliations

    • Laboratory of Immunology, Saitama Shakaihoken Hospital, Saitama, Japan
    • ,
  • Kanji Sugita

      Affiliations

    • Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan

Received 12 December 2009 ,Revised 24 June 2010 ,Accepted 28 June 2010.

References 

  1. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–776
  2. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528–530
  3. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370:650–652
  4. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195:161–169
  5. Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002;8:1433–1437
  6. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;108:6207–6215
  7. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  8. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35
  9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–809
  10. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182:1223–1230
  11. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–163
  12. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–162
  13. Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113
  14. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and death domain-containing receptor for TRAIL. Science. 1997;277:815–821
  15. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818–821
  16. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997;7:813–820
  17. Rowinsky EK. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor–related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005;23:9394–9407
  18. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007;25:1390–1395
  19. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621–3630
  20. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007;13:6187–6194
  21. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber cancer institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616–3622
  22. Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia. 1995;9:815–820
  23. Karawajew L, Wuchter C, Ruppert V, et al. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia. 1997;11:1245–1252
  24. Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110:154–160
  25. Iijima K, Sugita K, Inukai T, et al. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome. Leukemia. 2000;14:1598–1605
  26. Uno K, Inukai T, Kayagaki N, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 2003;101:3658–3667
  27. Inukai T, Zhang X, Goto M, et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia. 2006;20:2119–2129
  28. van Noesel MM, van Bezouw S, Salomons GS, et al. Tumor-specific down-Regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002;62:2157–2161
  29. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 2001;507:381–385
  30. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–5588
  31. Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505–512
  32. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem. 1996;270:7795–7798
  33. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1- and TNF receptor-induced cell death. Cell. 1996;85:803–815
  34. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  35. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481–490
  36. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81:513–523
  37. Duan H, Dixit VM. RAIDD is a new ‘death’ adaptor molecule. Nature. 1997;385:86–89
  38. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611–620
  39. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599–609
  40. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol. 2003;23:1278–1291
  41. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003;10:356–364
  42. Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005;3:335–343
  43. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L//TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L//TRAIL. Oncogene. 2008;27:490–498
  44. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004;64:5078–5083
  45. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141–143
  46. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4(DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis. 2008;13:756–770
  47. Shetty S, Graham BA, Brown JG, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005;25:5404–5416
  48. Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002;21:3121–3129
  49. Shiraishi T, Yoshida T, Nakata S, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005;65:6364–6370
  50. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279:45495–45502

PII: S0301-472X(10)00289-4

doi: 10.1016/j.exphem.2010.06.014

Experimental Hematology
Volume 38, Issue 10 , Pages 885-895 , October 2010

Article Tools

* Image Usage & Resolution